Lilly’s Donanemab Delay: Labeling, Real-World Operationalization May Be Reason For Adcomm

Close watchers of Lilly’s Alzheimer’s drug believe FDA’s last-minute advisory committee request is to deal with how to translate a complicated trial design into label recommendations, not because the agency is thinking of rejecting the drug, which had been seen as a shoo-in for approval.